hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06384625, orgStudyIdInfo id: 361378, briefTitle: Air Pollution Intervention for Cardiovascular Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-02-01, completionDateStruct date: 2025-02-01, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: University of Montana, class: OTHER, collaborators name: Providence Heart Institute, descriptionModule briefSummary: This pilot study (n=20) is a prospective evaluation of the implementation of an indoor air pollution intervention among patients who have undergone recent percutaneous coronary intervention procedures. The intervention, called Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education (AIRWISE), is focused on improving indoor air quality through air filtration, education, and behavioral recommendations. All participants will receive the AIRWISE intervention with the objective of evaluating acceptance and use of the individual intervention components. This implementation study will inform the submission of a larger NIH proposal for a randomized trial. The central study hypothesis is that an intervention program with educational strategies and visual behavioral cues will increase knowledge and awareness of air pollution exposures among the participants and lead to improved intervention compliance., conditionsModule conditions: Coronary Heart Disease, conditions: Cardiovascular Diseases, conditions: Environmental Exposure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: AIRWISE, outcomesModule primaryOutcomes measure: Evaluate the implementation of an indoor air pollution intervention., secondaryOutcomes measure: Fine particulate matter (PM2.5), secondaryOutcomes measure: Life's Essential 8, eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06384612, orgStudyIdInfo id: Adnan Menderes U, briefTitle: The Effect Of The Use Of Pocket Cards In An Undergraduate Nursıng, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-09-13, primaryCompletionDateStruct date: 2022-05-22, completionDateStruct date: 2023-07-13, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Aydin Adnan Menderes University, class: OTHER, descriptionModule briefSummary: The aim of this study is to examine the effect of the use of pocket cards by students taking the "Care of a Child with Special Needs" course on students' self-efficacy perceptions and course success.1. H01. There is no difference between the self-efficacy perception scores of the students in the group who use pocket cards in the care of children with special needs course and the students in the group who do not use pocket cards.2. H02. There is no significant difference between the course success scores of the students in the group who use pocket cards in the care of children with special needs course and the students in the group who do not use pocket cards., conditionsModule conditions: Student, conditions: Self Efficacy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: experimental, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 128, type: ACTUAL, armsInterventionsModule interventions name: use of pocket cards, outcomesModule primaryOutcomes measure: Self-Efficacy Perception Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 22 Years, stdAges: ADULT, contactsLocationsModule locations facility: Bircan Kahraman Berberoğlu, city: Efeler, state: Aydin, zip: 0900, country: Turkey, hasResults: False
protocolSection identificationModule nctId: NCT06384599, orgStudyIdInfo id: CS-190, briefTitle: VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2026-06-01, completionDateStruct date: 2026-06-01, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Adagio Medical, class: INDUSTRY, descriptionModule briefSummary: The PMCF is a prospective, single-arm, multi-center, controlled study of up to 130 patients designed to collect safety and performance data regarding the use of the Adagio VT Cryoablation System in the treatment of recurrent ventricular tachycardia., conditionsModule conditions: Ventricular Tachycardia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 130, type: ESTIMATED, armsInterventionsModule interventions name: VT Cryoablation System, outcomesModule primaryOutcomes measure: Primary Performance Endpoint, primaryOutcomes measure: Primary Safety Endpoint, secondaryOutcomes measure: Secondary Performance Endpoint, secondaryOutcomes measure: Secondary Safety Endpoint, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Essex Cardiothoracic Centre, city: Basildon, state: Essex, zip: SS16 5NL, country: United Kingdom, contacts name: Neil Srinivasan, role: CONTACT, geoPoint lat: 51.56844, lon: 0.45782, hasResults: False
protocolSection identificationModule nctId: NCT06384586, orgStudyIdInfo id: CD J8855, briefTitle: Investigation of Dietary Supplement Liquid Shot Products on Mental Energy, Cognition (Acuity),and Mood, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-11-17, primaryCompletionDateStruct date: 2022-12-22, completionDateStruct date: 2022-12-22, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: The Water Street Collective, class: INDUSTRY, collaborators name: HCD Research, collaborators name: British American Tobacco (Investments) Limited, descriptionModule briefSummary: This is a single center, randomized, double blind, placebo-controlled, crossover study to determine the acute effect of a developmental dietary supplement liquid shot product on cognitive task performance and perceived effect measures related to mood and mental energy. The study will be conducted in healthy participants., conditionsModule conditions: Cognition, conditions: Mental Fatigue, conditions: Mood, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 45, type: ACTUAL, armsInterventionsModule interventions name: Placebo shot, interventions name: Functional energy shot, outcomesModule primaryOutcomes measure: Mental energy via Cognitive Demand Battery (CDB) Performance Index; for the functional energy shot versus placebo shot., secondaryOutcomes measure: Mental energy via Cognitive Demand Battery (CDB) Accuracy score for the functional energy shot versus placebo shot., secondaryOutcomes measure: Change in performance on Corsi blocks task for functional energy shot versus placebo, secondaryOutcomes measure: Change in performance on Rapid Visual Information Processing (RVIP) for functional energy shot versus placebo, secondaryOutcomes measure: Change in performance on Numeric working memory for functional energy shot versus placebo, secondaryOutcomes measure: Change in performance on Serial subtraction task for functional energy shot versus placebo, secondaryOutcomes measure: Change in Mood via Visual Analogue Scales (VAS) during Cognitive Demand Battery (CDB), for functional energy shot versus placebo, secondaryOutcomes measure: Change in physiological state via Profile Of Mood States (POMS) during Cognitive Demand Battery (CDB), for functional energy shot versus placebo, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: Schlesinger Group New Jersey, city: Iselin, state: New Jersey, zip: 08330, country: United States, geoPoint lat: 40.57538, lon: -74.32237, hasResults: False
protocolSection identificationModule nctId: NCT06384560, orgStudyIdInfo id: 2023-508707-20-00, briefTitle: Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5), acronym: PREOPANC-5, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2028-03, completionDateStruct date: 2028-03, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Amsterdam UMC, location VUmc, class: OTHER, collaborators name: Maastricht University Medical Center, collaborators name: Erasmus Medical Center, collaborators name: St. Antonius Hospital, descriptionModule briefSummary: Since patients with borderline resectable pancreatic cancer (BRPC) have a limited life expectancy, it is important to improve treatment strategies. Therefore, the objective of this study is to investigate whether neoadjuvant triple treatment chemotherapy, immunotherapy and radiotherapy, followed by surgery and chemotherapy and immunotherapy survival in patients with BRPC., conditionsModule conditions: Borderline Resectable Pancreatic Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 66, type: ESTIMATED, armsInterventionsModule interventions name: Pembrolizumab, outcomesModule primaryOutcomes measure: Percentage of patients with progression free survival at 18 months (RECIST 1.1), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06384547, orgStudyIdInfo id: VRDN-001-303, briefTitle: A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2026-01, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Viridian Therapeutics, Inc., class: INDUSTRY, descriptionModule briefSummary: The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). The primary objective of this clinical trial is to evaluate the safety and tolerability of VRDN-001 in patients with TED., conditionsModule conditions: Thyroid Eye Disease, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A randomized, active controlled, safety and tolerability study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with thyroid eye disease (TED), primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 212, type: ESTIMATED, armsInterventionsModule interventions name: VRDN-001 10 mg/kg, interventions name: VRDN-001 3 mg/kg, outcomesModule primaryOutcomes measure: Treatment Emergent Adverse Event (TEAE) incidence rate, secondaryOutcomes measure: Change from baseline in proptosis in the study eye as measured by exophthalmometer at Week 15, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: United Medical Research Institute, city: Inglewood, state: California, zip: 90301, country: United States, contacts name: James Peace, MD, role: CONTACT, phone: 310-645-4673, geoPoint lat: 33.96168, lon: -118.35313, hasResults: False
protocolSection identificationModule nctId: NCT06384534, orgStudyIdInfo id: PVD_6MWD_SOT, briefTitle: Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-11, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: University of Zurich, class: OTHER, descriptionModule briefSummary: The investigators aim to study the effect of SOT in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH)., conditionsModule conditions: Pulmonary Vascular Disorder, conditions: Chronic Thromboembolic Pulmonary Hypertension, conditions: Pulmonary Arterial Hypertension, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Each participant is its own control, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: 6-minute walk distance (6MWD) test on ambient air, interventions name: 6-minute walk distance test with supplemental oxygen, outcomesModule primaryOutcomes measure: 6-minute walk distance (6MWD) with supplemental oxygen therapy (SOT) vs. ambient air, secondaryOutcomes measure: SpO2 at rest and peak 6MWD with SOT vs. ambient air, secondaryOutcomes measure: Heart rate at rest and peak 6MWD with SOT vs. ambient air, secondaryOutcomes measure: Borg dyspnea scale at rest and peak 6MWD with SOT vs. ambient air, secondaryOutcomes measure: Borg leg fatigue scale at rest and peak 6MWD with SOT vs. ambient air, secondaryOutcomes measure: Blood pressure at rest and peak 6MWD with SOT vs. ambient air, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Zürich, city: Zurich, zip: 8091, country: Switzerland, contacts name: Silvia Ulrich, Prof. Dr., role: CONTACT, phone: 0041 44 255 22 20, email: silvia.ulrich@usz.ch, contacts name: Mona Lichtblau, Dr., role: CONTACT, phone: +41442552220, email: mona.lichtblau@usz.ch, contacts name: Silvia Ulrich, Prof. Dr., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 47.36667, lon: 8.54999, hasResults: False
protocolSection identificationModule nctId: NCT06384521, orgStudyIdInfo id: STUDY00000500, briefTitle: Lifestyle MIND- Feasibility for Randomized Wait-list Control Trial, acronym: MIND, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: The University of Texas Health Science Center at San Antonio, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to examine if it is feasible to randomly assign people into two groups and participate in Lifestyle MIND (Mental Illness and/N' Diabetes) at two different times. Lifestyle MIND is a diabetes lifestyle intervention recently developed for people with serious mental illness (SMI). It is known to be helpful for people with SMI who complete it, but the investigators do not know the effect in comparison to those who do not participate in it. The main questions it aims to answer are:* Does Lifestyle MIND improve diabetes control among people with SMI?* Will the effect of Lifestyle MIND be sustained 10 weeks after program completion?* From the provider's perspective, what are the barriers of achieving optimal diabetes treatment outcomes for patients with SMI?Researchers will compare outcomes of participants in the intervention with those in the wait-list control arm, to see if there will be significant differences in blood glucose level, compliance of diabetes self-management, time staying active, number of emergency department (ED) visits and psychiatric hospitalization, and subjective well-being., conditionsModule conditions: Type 2 Diabetes Mellitus, conditions: Serious Mental Illness, conditions: Schizophrenia, conditions: Major Depression, conditions: Bipolar Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: FACTORIAL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Lifestyle MIND, outcomesModule primaryOutcomes measure: Hemoglobin A1c (HbA1c), primaryOutcomes measure: Summary of Diabetes Self-Care Activities (SDSCA) Questionnaire, primaryOutcomes measure: Hours of Active and Sedentary Behavior, primaryOutcomes measure: Number of emergency department (ED) visits and psychiatric hospitalizations, primaryOutcomes measure: Satisfaction with Life Scale (SWLS), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Texas Health Science Center at San Antonio, city: San Antonio, state: Texas, zip: 78229, country: United States, contacts name: Chinyu Wu, PhD, role: CONTACT, phone: 210-567-8890, email: wuc7@uthscsa.edu, contacts name: Chinyu Wu, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Bradley Tragord, ScD, role: SUB_INVESTIGATOR, geoPoint lat: 29.42412, lon: -98.49363, hasResults: False
protocolSection identificationModule nctId: NCT06384495, orgStudyIdInfo id: STUDY00021475, briefTitle: How Does Cerebellar tDCS Alter Intracortical Inhibition Over Time?, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-15, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: University of Minnesota, class: OTHER, descriptionModule briefSummary: Combining cortical tDCS with behavioral interventions has been shown to have beneficial outcomes in individuals post-stroke. However, cerebellar tDCS is a fairly new approach for individuals with unilateral cortical stroke and there has not been reports of duration of effect of tDCS applied to the cerebellum in this population.Information gained from this study will serve to fill knowledge gaps on the duration of effect of cerebellar tDCS and the effects of polarity.The purpose of this study is to determine the duration of effect of ventro-lateral cerebellar transcranial direct current stimulation (tDCS) in healthy adults through cortical excitability (CE), cognitive, language and motor assessment measures. Primary aim: Compare baseline CE from left motor cortex of first dorsal interosseous (FDI) and orbicularis oris (OO) areas to CE post cerebellar tDCS at 15 minutes, 45 minutes and 75 minutes. Single-pulse and paired-pulse transcranial magnetic stimulation (TMS) will be used to measure and compare stimulus response curve (S/R curve), cortical silent period (CSP) and short-interval intracortical inhibition (SICI) in the hand area and facial area of the left primary motor cortex at each time point.Secondary aim: Compare baseline performance on cognition, motor learning and language tasks to performance at 15, 45 and 75 minutes after receiving tDCS. Digit Symbol Substitution Test (DSST), Serial Reaction Time Test (SRTT) and Lexical Decision tasks will be presented via a computer interface., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: REAL-A, interventions name: REAL-C, interventions name: SHAM, outcomesModule primaryOutcomes measure: stimulus/response curve (S/R Curve), primaryOutcomes measure: Cortical Silent Period (CSP), primaryOutcomes measure: Short-interval Intracortical Inhibition (SICI)., secondaryOutcomes measure: Digit Symbol Substitution Test (DSST), secondaryOutcomes measure: Serial Reaction Time Test (SRTT), secondaryOutcomes measure: Lexical Decision Task, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06384482, orgStudyIdInfo id: SNC115-DLL3 CART-101, briefTitle: SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-30, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-04-25, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: Shanghai Simnova Biotechnology Co.,Ltd., class: INDUSTRY, collaborators name: Shanghai Chest Hospital, descriptionModule briefSummary: This study is a FIH dose escalation clinical study, with single arm, open label and design, in order to observe the preliminary safety and Pharmacokinetic of SNC115 Injection in participants with Recurrent/refractory small cell lung cancer and Lung large cell neuroendocrine carcinoma., conditionsModule conditions: Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: SNC115 injection, outcomesModule primaryOutcomes measure: Safety of SNC115 Injection, primaryOutcomes measure: Safety of SNC115 Injection, secondaryOutcomes measure: -Efficacy of SNC115 Injection, secondaryOutcomes measure: -Efficacy of SNC115 Injection, secondaryOutcomes measure: -Efficacy of SNC115 Injection, secondaryOutcomes measure: -Efficacy of SNC115 Injection, secondaryOutcomes measure: -Efficacy of SNC115 Injection, secondaryOutcomes measure: -Efficacy of SNC115 Injection, otherOutcomes measure: -PK characteristic of SNC115 Injection., otherOutcomes measure: -PK characteristic of SNC115 Injection., otherOutcomes measure: PK characteristic of SNC115 Injection., otherOutcomes measure: PK characteristic of SNC115 Injection., otherOutcomes measure: PK characteristic of SNC115 Injection., otherOutcomes measure: PK characteristic of SNC115 Injection., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Chest Hospital, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200030, country: China, contacts name: Hua Zhong, MD/PhD, role: CONTACT, phone: 021-22200000, email: ctqxkyy@163.com; eddiedong8@hotmail.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False